2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-16,Kite Announces Appointment Of Renowned Cancer Researcher, Owen N. Witte, M.D., To Its Board Of Directors
2017-03-14,Kite Pharma Highlights Publication From The National Cancer Institute Demonstrating Durable Complete Remissions In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy And Anti-CD19 CAR T-Cell Therapy
2017-03-14,Rev's Forum: Don't Underestimate the Power of a Plodding Market
2017-03-13,Market Takes 'National Napping Day' Seriously
2017-03-13,Biotech Leads the Way Again Today
2017-03-13,Rev's Forum: Bulls Still Believe, but Negative Catalysts are Building
2017-03-10,Late Market Rally but No Bounce for Bulls
2017-03-09,Shark Bites: Market Needs a Bounce in Its Step
2017-03-09,Market Set Up for Oversold Bounce
2017-03-08,Watching Financials and Biotech in This Tepid Market
2017-03-08,Kite Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2017-03-07,Inside the Head of a Trader: Tuesday Morning With James 'Rev Shark' Deporre
2017-03-07,Woe to Those Who Are Trapped When the Daily Pattern Is Broken
2017-03-06,Still Watching Price Action, but Playing Strong Defense
2017-03-06,Kite To Present At March 2017 Investor Conferences
2017-03-05,Richard L. Wang Named Chief Executive Officer Of Fosun Kite Biotechnology Co., Ltd., A Joint Venture To Lead Development Of Axicabtagene Ciloleucel And Other Engineered T-Cell Therapies For Treatment Of Cancers In China
2017-03-02,With Big Hopes for Cancer Drug, Kite Raising $350M
2017-03-02,Market Taking a Break, but Probably Not for Long
2017-03-02,Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
2017-03-02,Kite Announces Pricing Of Public Offering Of Common Stock
2017-03-02,7 Stocks Trending With Monster Volume
2017-03-02,Kite Announces Commencement Of Public Offering Of Common Stock
2017-02-28,It Wasn't a Good Change, but at Least It Was a Change
2017-02-28,Kite Pharma CAR-T Therapy Shows Results in Lymphoma Patients
2017-02-28,Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients
2017-02-28,Kite Reports Fourth Quarter And Full Year 2016 Financial Results
2017-02-28,Kite Announces Positive Topline Primary Results Of Axicabtagene Ciloleucel From First Pivotal CAR-T Trial In Patients With Aggressive Non-Hodgkin Lymphoma
2017-02-27,Kite To Report Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017
2017-02-07,Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment
2017-01-10,Biotech Premarket Movers: ILMN, NSTG, KITE
2017-01-10,Kite Pharma And Fosun Pharma Establish Joint Venture In China To Develop And Commercialize Autologous T-Cell Therapies To Treat Cancer
2017-01-09,Kite Pharma Establishes A Strategic Partnership With Daiichi Sankyo To Develop And Commercialize Axicabtagene Ciloleucel (KTE-C19) In Japan
2017-01-05,Kite Pharma Enhances Commercial Expertise With The Appointment Of Ian T. Clark To Its Board Of Directors
2017-01-05,What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
2017-01-04,Kite Pharma To Present At The 35th Annual J.P. Morgan Healthcare Conference
2017-01-03,Kite Pharma Submits Investigational New Drug (IND) Application For KITE-718, An Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 And MAGE A6
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2016-12-19,Kite Pharma Announces Successful Defense Of Roberts Patent And Intent To Appeal U.S. Patent And Trademark Office Decision On A Narrow Patent Focused On Select CD28 CAR-T Products
2016-12-14,The Worst Biopharma CEOs of 2016 Are ...
2016-12-13,Kite Pharma And Vitruvian Networks Enter Strategic Partnership To Develop Best-In-Class Logistics And Data Analytics Software For Engineered T-cell Therapies At Commercial Scale
2016-12-12,Kite Pharma Announces Publication Of T-Cell Therapy Targeting Mutant KRAS In Cancer By The National Cancer Institute (NCI) In New England Journal Of Medicine
2016-12-06,Kite Pharma Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society Of Hematology
2016-12-05,Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
2016-12-05,Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out
2016-12-04,Kite Pharma Reports 82 Percent Of Patients Achieved Complete Remission In Preliminary Analysis From Phase 1 ZUMA-3 And ZUMA-4 Trials Of KTE-C19 In Adult And Pediatric Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
2016-12-01,Kite Pharma Appoints Jian Irish, PhD As Senior Vice President Of Supply Chain
2016-11-30,Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
2016-11-28,Four Stocks Ready for Breakouts -- Check These Charts
2016-11-21,Kite Pharma To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society Of Hematology Annual Meeting
2016-11-17,Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!
2016-11-09,Kite Pharma Reports Third Quarter 2016 Financial Results
2016-11-09,'Mad Money' Lightning Round: Ollie's Bargain Outlet, Walmart Are Winners
2016-11-08,Jim Cramer's 'Mad Money' Recap: If This Election Hits Stocks, Here's What You Should Do
2016-11-03,Kite Pharma To Present KTE-C19 Data From Interim Analysis Of The ZUMA-1 Pivotal Trial In Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) And Transformed Follicular Lymphoma (TFL) At The 2016 American Society Hematology Annual Meeting
2016-11-02,Kite Pharma To Report Third Quarter 2016 Financial Results On November 9, 2016
2016-10-28,Kite Pharma To Present At November 2016 Investor Conferences
2016-10-19,Kite Pharma Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day
2016-10-17,Trader's Daily Notebook: You Might Consider Selling Facebook
2016-10-13,Chris Nowers, Head Of Europe, Kite Pharma (Photo: Business Wire)
2016-10-11,Kite Pharma To Host Investor Day On October 18, 2016 Spotlighting An Industry-Leading CAR/TCR Pipeline, Next Generation Research And Development, And KTE-C19 Launch Readiness
2016-10-07,Kite Pharma Presents 12-Month Follow-Up Data From ZUMA-1 Phase 1 At The European Society For Medical Oncology (ESMO) Annual Congress
2016-10-06,Kite Pharma Initiates Phase 1b/2 Combination Study For KTE-C19 And Atezolizumab In Patients With Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2016-09-29,Christine Cassiano, SVP, Corporate Communications & Investor Relations, Kite Pharma (Photo: Business Wire)
2016-09-27,Kite Pharma (KITE) Stock Surges on Lymphoma Trial, Cowen: Drug's Efficacy 'Impressive'
2016-09-26,Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next
2016-09-26,Kite Pharma Announces Positive Topline KTE-C19 Data From ZUMA-1 Pivotal Trial In Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
2016-09-21,Kite Pharma Isn't Airborne Yet
2016-09-20,Kite Pharma Announces Exclusive License With The National Institutes Of Health For Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates To Treat Solid Tumors Expressing Mutated KRAS
2016-09-12,5 Questions and Answers Take a Measure of Biotech Investor Sentiment
2016-08-31,Kite Pharma To Participate In September 2016 Investor Conferences
2016-08-19,Kite Pharma Advisors And Scientific Pioneers In Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
2016-08-18,Ratings Changes Today
2016-08-08,Kite Pharma Reports Second Quarter 2016 Financial Results
2016-08-03,Kite Pharma To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-01,Kite Pharma To Report Second Quarter 2016 Financial Results On August 8, 2016
2016-07-29,Bullish Two Hundred Day Moving Average Cross - KITE
2016-07-27,Kite Pharma Announces Exclusive License With The National Institutes Of Health For Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate To Treat B-Cell Malignancies
2016-07-25,Kite Pharma Licenses Enabling Technology For The Development Of Off-the-Shelf Allogeneic T-Cell Therapies
2016-07-08,Notable Friday Option Activity: KITE, VSI, QUAD
2016-07-08,Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks
2016-07-07,Kite Pharma Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1)
2016-07-07,Juno Patient Deaths Crash Cancer-Killing CAR-T Party
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-23,Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'
2016-06-20,Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
2016-06-20,Kite Pharma Expands Development Of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers In Partnership With The National Cancer Institute (NCI)
2016-06-08,Kite Pharma To Highlight Key Data From CAR T-Cell Therapy Pipeline In Oral Presentations At The 2016 European Hematology Association (EHA) Annual Congress
2016-06-06,Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma
2016-06-06,Kite Pharma Announces The First Meta-Analysis Of Outcomes In Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
2016-06-06,Kite Pharma Presents Ongoing Complete Responses At 9 Months In Phase 1 Of ZUMA-1 In Patients With Chemorefractory Non-Hodgkin Lymphoma
2016-06-02,Kite Pharma And Cell Design Labs Announce Exclusive Research Collaboration Using Molecular 'On/Off Switches' For CAR T-Cell Immunotherapies
2016-06-01,Kite Pharma Granted Access To Priority Medicines (PRIME) Regulatory Support For KTE-C19 In The Treatment Of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)
2016-05-31,Kite Pharma To Highlight Key Data From Engineered CAR T Cell Therapy Pipeline At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-27,Kite Pharma To Present At June 2016 Investor Conferences
2016-05-20,Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation
2016-05-16,Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson As Chief Financial Officer
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-09,Kite Pharma Reports First Quarter 2016 Financial Results
2016-05-03,Kite Pharma To Report First Quarter 2016 Financial Results On May 9, 2016
2016-05-02,Kite Pharma Announces FDA Orphan Drug Designations For KTE-C19 In Five Additional Indications
2016-04-28,Kite Pharma Announces Presentations At The Annual Meeting Of The American Society Of Gene & Cell Therapy (ASGCT)
2016-04-19,Kite Pharma Presents Updated Phase 1 Results From ZUMA-1 At The American Association Of Cancer Research (AACR) Annual Meeting
2016-04-18,Kite Pharma Commends Scientific Advisory Board Members On Awards Received From The American Association Of Cancer Research (AACR)
2016-04-16,Kite Pharma Announces Review Of National Cancer Institute's Manufacturing Facilities
2016-04-15,Kite Pharma Announces Key Presentations On KTE-C19 And Engineered Cell Therapy Pipeline Programs At The Annual Meeting Of The American Association For Cancer Research (AACR)
2016-03-17,Kite Pharma Announces Clinical Collaboration To Evaluate Two Novel Immunotherapies For Patients With Non-Hodgkin Lymphoma
2016-03-16,Kite Pharma Announces Clinical And Manufacturing Updates On KTE-C19 And MAGE-A3 Product Candidates At The Annual Meeting Of The American Association For Cancer Research (AACR)
2016-03-16,Kite Pharma Deepens Cell Manufacturing And Operations Expertise With Appointment Of Tim Moore
2016-03-03,Kite Pharma To Present At March 2016 Investor Conferences
2016-02-29,Kite Pharma Reports Fourth Quarter And Full-Year 2015 Financial Results
2016-02-24,Kite Pharma Augments Commercial Leadership Team
2016-02-24,Kite Pharma To Report Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016
2016-02-24,'Mad Money' Lightning Round: Buy Lockheed Martin at These Prices
2016-02-23,Jim Cramer's 'Mad Money' Recap: Industrials Are Looking Good Again
2016-02-16,Kite Pharma To Participate In The 2016 RBC Capital Markets Global Healthcare Conference
2016-01-26,Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy
2016-01-13,Kite Pharma And Leiden University Medical Center Sign Research And License Agreement For T Cell Receptors Targeting HPV-Associated Cancers
2016-01-09,2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks
2016-01-07,Kite Pharma Expands Its Clinical And Research Partnership With The National Cancer Institute (NCI) For Next-Generation CAR Programs To Treat B-Cell Malignancies
2016-01-06,Kite Pharma To Present At The 34th Annual J.P. Morgan Healthcare Conference
2016-01-05,Editas' IPO Challenge: Edit Investor Expectations as Well as Diseased Genes
2016-01-01,Feuerstein's Heroes and Zeroes of Biotech Investing in 2015
2015-12-21,Kite Pharma Appoints Industry Leader Shawn Cline Tomasello As Chief Commercial Officer
2015-12-14,Cancer Immunotherapy ETF Offers High Growth Investing Potential
2015-12-14,Cancer Immunotherapy ETF Offers High Growth Investing Option
2015-12-11,Kite Pharma Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-12-10,Kite Pharma Announces Pricing Of Public Offering Of Common Stock
2015-12-08,Kite Pharma Announces Proposed Public Offering Of Common Stock
2015-12-07,Kite Pharma Announces Clinical Biomarker Results Of Anti-CD19 CAR T Cell Therapy At The 57th American Society Of Hematology Annual Meeting (ASH)
2015-12-07,Kite Pharma Presents Phase 1 Results From ZUMA-1 At The 57th American Society Of Hematology (ASH) Annual Meeting
2015-12-07,Kite Pharma Receives FDA Breakthrough Therapy Designation For KTE-C19 For The Treatment Of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
2015-12-07,Kite Pharma Initiates The ZUMA-4 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Children And Young Adults
2015-12-03,Kite Pharma And GE Global Research Announce Strategic Collaboration To Automate Manufacturing Of Engineered T Cell Therapies
2015-12-02,Kite Pharma Initiates The ZUMA-3 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Adult Subjects
2015-11-22,Goldman Sachs Says These 12 Small-Cap Stocks Are Worth Buying
2015-11-18,Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy
2015-11-12,Kite Pharma Reports Third Quarter 2015 Financial Results And Provides Business Update
2015-11-09,Kite Pharma To Host Third Quarter 2015 Financial Results Conference Call And Webcast
2015-11-09,Kite Pharma Initiates Phase 2 Clinical Study Of KTE-C19 (ZUMA-2) In Patients With Relapsed Or Refractory Mantle Cell Lymphoma (r/r MCL) To Support Registration For A Second Indication
2015-11-05,Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data
2015-11-05,Kite Pharma To Present Four Abstracts, Including Safety And Efficacy Data From The KTE-C19 Phase 1 Study In Patients With Refractory, Aggressive NHL (ZUMA-1), At The 57th American Society Of Hematology Annual Meeting (ASH)
2015-11-04,Kite Pharma To Present At Upcoming Investor Conferences In November 2015
2015-11-02,Before the Move: Watch Cellectis Into UCART19 Data
2015-11-02,Kite Pharma Initiates ZUMA-1 Phase 2 In Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) To Support Registration Of KTE-C19
2015-10-27,Kite Pharma And Alpine Immune Sciences Announce Research Collaboration And License Agreement To Enhance Immune Response In The Tumor Microenvironment
2015-10-22,Northwest Bio Bothers British Bestie for Bounteous Bucks
2015-10-20,Kite Pharma Announces Exclusive License With The National Institutes Of Health For T Cell Receptor (TCR)-Based Products To Treat Tumors Expressing MAGE
2015-10-15,Kite Pharma Receives Positive Opinions For Orphan Drug Designation In The European Union (EU) For KTE-C19 In Three Additional Hematological Indications
2015-10-07,Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., On The Prestigious Medal Of Honor Award From The American Cancer Society
2015-10-01,Kite Pharma Announces Peer-Reviewed Publication Of T Cell Receptor Based Product Candidate To Treat HPV-Associated Cancers
2015-09-24,Kite Pharma To Present At IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing The Next Generation Of Cancer Immunotherapies Conference
2015-09-15,Franz B. Humer, Former Chairman And CEO Of Roche Group, Appointed To Kite Pharma's Board Of Directors
2015-09-14,Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
2015-09-11,Kite Pharma Receives Positive Opinion For Orphan Drug Designation In The European Union For KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
2015-09-03,Kite Pharma Commends Honors Conferred To Scientific Advisory Board Members For Their Significant Contributions To Medicine
2015-09-03,Kite Pharma To Participate In Upcoming Investor Conferences In September 2015
2015-09-01,The Numbers Behind Biotech's Horrible, No Good, Awful August
2015-08-26,Biotech Selloff Has No Effect on Cellectis Advances: CEO
2015-08-26,Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO
2015-08-21,Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
2015-08-19,Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
2015-08-17,Kite Pharma (KITE) Stock Rises, Patient Death Not Related to Treatment Candidate
2015-08-17,Kite Pharma Provides Update On KTE-C19 Clinical Trial
2015-08-14,Kite Pharma To Hold Conference Call To Provide A Corporate Update On Monday, August 17, 2015
2015-08-10,Kite Pharma Reports Second Quarter 2015 Financial Results
2015-08-06,Kite Pharma To Host Second Quarter 2015 Financial Results Conference Call And Webcast
2015-08-05,Kite Pharma To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-08-03,Kite Pharma (KITE) Stock Is the 'Chart of the Day'
2015-08-03,Kite Pharma May Soon Be Flying High
2015-08-03,Chart of the Day: KITE
2015-07-15,'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
2015-07-10,5 Stocks Ready for Breakouts -- Must-See Charts
2015-07-01,Kite Pharma And The Leukemia & Lymphoma Society(R) Enter Into Collaboration To Enhance The Development Of KTE-C19 In Refractory Aggressive Non-Hodgkin Lymphoma And Launch CAR T-Cell Therapy Educational Programs
2015-07-01,'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
2015-06-29,Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership
2015-06-22,Kite Pharma And Bluebird Bio Announce Strategic Collaboration To Advance Second Generation TCR Cell Therapy Products To Treat HPV-Associated Cancers
2015-06-19,'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup
2015-06-18,Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today
2015-06-16,Kite Pharma To Host Investor Day On June 23, 2015
